1. Foundations of Patentability for Bioengineered Vaccines

For a bioengineered vaccine to be patentable, most jurisdictions require these criteria:

1. Patentable Subject Matter
   • Must fall under statutory categories like composition of matter, process, manufacture, or improvement thereof.
   • Naturally occurring organisms or genes per se are generally not patentable unless they are modified or engineered to produce new properties.
2. Novelty (Newness)
   • The vaccine or its components must not be disclosed in prior art, including scientific literature, patents, or public use.
3. Inventive Step / Non-Obviousness
   • The invention must not be obvious to a person skilled in biotechnology.
   • For vaccines, this could include a novel antigen presentation, adjuvant formulation, or delivery platform.
4. Utility / Industrial Applicability
   • The invention must have a specific, credible therapeutic or prophylactic use.
5. Ethical Considerations / Public Order
   • Some jurisdictions (India, Europe) exclude inventions contrary to ordre public or morality, which may affect certain biotechnological inventions.

📘 Key Case Laws

Below are five significant cases that clarify patentability issues in vaccine and bioengineered technology.

🔹 1. Diamond v. Chakrabarty (1980, U.S.)

Facts:

• A genetically modified bacterium capable of degrading crude oil was engineered.
• The patent application claimed a living, modified organism.

Decision:

• The U.S. Supreme Court held that genetically engineered organisms are patentable, because they are not naturally occurring and have “markedly different characteristics from any found in nature.”

Relevance to Vaccines:

• Bioengineered vaccine vectors (like recombinant viral or bacterial strains) are patentable if they are engineered to have novel antigenic or functional properties.

Lesson:

• Natural viruses or bacterial strains cannot be patented, but modified or recombinant forms can be patented if they exhibit new traits.

🔹 2. Harvard Mouse Case (1988, U.S.)

Facts:

• Harvard researchers developed a genetically modified mouse (the “oncomouse”) predisposed to cancer for research purposes.

Decision:

• The patent was granted in the U.S. but faced restrictions in Europe; it established that engineered animals are patentable if they are not naturally occurring.

Relevance to Vaccines:

• This principle supports patenting engineered animal models or viral vectors used in vaccine development.

🔹 3. Merck v. Integra Lifesciences (2005, U.S.) – Use of Natural Products in Biotechnology

Facts:

• Integra’s patent involved compounds derived from natural sources for inhibiting enzymes.
• Merck challenged for infringement; the Supreme Court addressed whether use of natural compounds in a technical method was patentable.

Decision:

• The Court confirmed that natural products may be patentable when applied in a novel and useful process.

Relevance to Vaccines:

• Plant-derived adjuvants or peptides used in vaccines are patentable if formulated or applied in a novel way.

🔹 4. Novartis v. Union of India (2013, India) – Inventive Step / Non-Obviousness

Facts:

• Novartis’ patent application for an incremental improvement in cancer drug was rejected because it lacked significant improvement in efficacy.

Decision:

• The Supreme Court emphasized that incremental modifications without enhanced efficacy or novelty do not constitute invention.

Relevance to Vaccines:

• Minor modifications to known vaccine vectors or adjuvants must demonstrate significant improvement, like enhanced immune response or stability, to be patentable in India.

🔹 5. Harvard Oncomouse & Ethical Restrictions – European Patent Office (EPO)

Facts:

• EPO initially granted patents for the Oncomouse but applied restrictions based on ethical considerations.

Decision:

• Under EPC Art. 53(a), inventions contrary to morality or public order (e.g., certain genetic modifications) can be refused.

Relevance to Vaccines:

• Some genetically modified viruses or live vaccine strains may be scrutinized for biosafety or ethical concerns. Patent applications must demonstrate safety and public utility.

🔹 6. Sequenom v. Ariosa Diagnostics (2015, U.S.) – Diagnostic Relevance for Biotechnology

Facts:

• Sequenom patented a method to detect fetal DNA in maternal blood.
• The Supreme Court invalidated it, citing that laws of nature or natural phenomena alone cannot be patented.

Relevance to Vaccines:

• Vaccine patents must involve engineered technology or methods, not merely the identification of natural antigens.

🔹 7. ACIP Vaccine Patent Litigation (Multiple, U.S.)

Facts:

• Patents covering adjuvant formulations or recombinant viral vectors in vaccines often faced challenges regarding obviousness.

Decision & Relevance:

• Courts consistently held that novel combinations of antigens with adjuvants that enhance immunogenicity in unexpected ways are patentable.
• Simply mixing known vaccine components without demonstrated synergistic effect is not patentable.

📌 Key Principles Illustrated

🧠 Practical Guidance for Bioengineered Vaccine Patents

✔️ Strategies to Strengthen Patentability

1. Claim specific engineered antigens or recombinant constructs, not natural viruses.
2. Include unexpected advantages like higher immunogenicity, broader strain coverage, or thermostability.
3. Emphasize novel processes (e.g., novel adjuvant incorporation, delivery methods).
4. Provide safety and efficacy data to support industrial applicability and ethical considerations.

❌ Pitfalls to Avoid

• Claiming a natural virus or antigen per se.
• Incremental changes without functional improvement.
• Broad claims without technical implementation.

Summary:
Bioengineered vaccine technologies are patentable if they are novel, inventive, and industrially applicable, particularly when the organism or antigen is engineered. Historical knowledge or mere discovery of natural antigens is not patentable, and ethical, safety, and public policy considerations play a key role.